| Name | Title | Contact Details |
|---|---|---|
Chulani Karunatilake |
Senior Vice President of Technical Operations | Profile |
Chulani Karunatilake |
Senior Vice President, Technical Operations | Profile |
Fruit Street delivers the CDC`s Diabetes Prevention Program using telehealth, wearable devices, and mobile applications. The diabetes prevention program is a 1-year long diet and lifestyle intervention designed to help pre-diabetic patients lose 5-7% of their weight through diet and lifestyle changes. The program is based on clinical research that was published in the New England Journal of Medicine in 2002 which showed that patients who complete the program have a 58% risk reduction for developing diabetes.
J B Dental Supply Co is a Carson, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Augusta Medical Systems, LLC was formed in 1999 and its owner, Michael Osbon, has a long history in office based urological products for the treatment of Erectile Dysfunction. Augusta Medical Systems was formed not only to deliver the best Vacuum
Mount Evans Hospice is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.